nLife Therapeutics is a nanomedicine biotechnology company based in Armilla (Granada) focused on developing therapeutic agents for disorders of the central nervous system. The company said it will use newly awarded funds to carry out research on CNS therapeutic agents. In September 2014 it received a $350,000 grant from the Michael J. Fox Foundation (about €273,000). Earlier, the company closed a €2 million financing round in June led by Healthequity. Caixa Capital Risc and Invercaria also participated in that round; those two VCs had previously invested €5 million in February 2012. Crossroad Biotech is also an investor in the company. nLife Therapeutics is a biotechnology company based in Granada, Spain, that develops oligonucleotides as therapeutic agents for CNS disorders. Led by CEO Andrés Montefeltro, the company's pipeline includes programs targeting Parkinson disease (NLF-PD), morbid obesity (NLF-MO), and major depressive disorder (NLF-MDD). The company closed a €2m funding round to advance its therapeutics, particularly to support development of its Parkinson disease program. Backers in the round include Caixa Capital Risc, Healthequity, and Invercaria. The funds will be used to progress its CNS-focused programs toward further development. nLife Therapeutics is a Granada, Spain–based company developing next-generation targeted nucleic acid treatments for central nervous system diseases. Its technology delivers conjugated nucleic acids linked to small chemicals to selected neurons after a single intranasal application. The company has launched siRNA-based programs targeting Parkinson's disease, morbid obesity and major depressive disorder. nLife raised €5m in funding and intends to use the proceeds to advance clinical trials for its treatments. Backers include la Caixa (through Caixa Capital Risc and Caixa Capital Biomed) and Invercaria (through the Jeremie fund), each investing €2.5m.

Total raised

$10M

Funding rounds

3

Latest round

Grant

Latest activity

Sep 2014